Neuromidine, tablets 20 mg 50 pcs

Neuromidin^® has direct stimulating effect on impulse conduction along the nerve fibers, inter-neuronal and neuromuscular synapses of CNS and peripheral nervous system.

The pharmacological action of Neuromidin^® is based on the combination of two mechanisms of action: blockade of potassium channels of the membrane of neurons and muscle cells; reversible inhibition of cholinesterase in synapses.

Neuromidine^® enhances the effect on smooth muscles not only of acetylcholine but also of adrenaline, serotonin, histamine and oxytocin.

Neuromidine^® has the following pharmacological effects:

– improves and stimulates impulse conduction in the nervous system and neuromuscular transmission;

– Increases smooth muscle organ contractility under the influence of agonists of acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, except potassium chloride;

– improves memory, inhibits the progressive course of dementia.

In preclinical studies Neuromidine^® had no teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic effects and did not affect the endocrine system.

Indications

Polyneuropathy,

• diseases of peripheral nervous system (mono- and polyneuropathy, polyradiculopathy, myasthenia and myasthenic syndrome of different etiology);
• CDS (bulbar paralysis and paresis;
• CNS diseases (bulbar paralysis and paresis; recovery period of organic CNS lesions accompanied by motor and/or cognitive disorders)
• intestinal atony (treatment and prevention) (additional for tablets).

.

Active ingredient

Ipidacrine

How to take, the dosage

Orally. Doses and duration of treatment are determined individually, depending on the severity of the disease.

Interaction

Neuromidine^® increases the sedative effect in combination with CNS depressants.

The effects and side effects are enhanced when combined with other cholinesterase inhibitors and m-cholinomimetic agents. In patients with myasthenia gravis, the risk of cholinergic crisis increases when Neuromidine^® is used concomitantly with other cholinergic agents.

The risk of bradycardia increases if β-adrenoblockers were used before starting treatment with Neuromidine^®.

Neuromidine^® may be used in combination with nootropic drugs.

Alcohol increases the side effects of the drug.

Limits the inhibitory effect on neuromuscular transmission and excitation along the peripheral nerves of local anesthetics, aminoglycosides, potassium chloride.

Special Instructions

There are no systematic data on the use of Neuromidin® in children.

Alcohol should be avoided during treatment (increases the side effects of the drug).

Impact on the ability to drive a car or perform work requiring increased speed of physical and mental reactions.

During treatment, you should refrain from driving a vehicle or engaging in potentially hazardous activities that require increased concentration and rapid psychomotor reactions.

Contraindications

• hypersensitivity to any of the ingredients of the drug;
• Epilepsy;
• extrapyramidal disease with hyperkinesias;
stenocardia;
• explicit bradycardia;
• bronchial asthma;
• mechanical obstruction of the bowel or urinary tract;
• vestibular disorders;
• gastric or duodenal ulcer in the acute stage;
• pregnancy (the drug increases uterine tone);
• lactation period;
• children under 18 years of age (there are no systematic data on its use).

With caution: in gastric and duodenal ulcer, thyrotoxicosis, diseases of the cardiovascular system, as well as in patients with obstructive diseases of the respiratory system in the anamnesis or in acute respiratory diseases.

Advanced for tablets

With caution: in lactase deficiency, lactose intolerance, lactose/isomaltose malabsorption syndrome, because the drug contains lactose.

Side effects

Induced by excitation of m-cholinoreceptors: salivation, increased sweating, palpitations, nausea, diarrhea, jaundice, bradycardia, epigastric pain, increased discharge of bronchial secretion, bronchospasm, seizures.

Salivation and bradycardia can be reduced by m-cholinoblockers (atropine, etc.). Increased uterine tone, skin allergic reactions.

Rarely (after using higher doses) dizziness, headache, chest pain, vomiting, general weakness, drowsiness, skin reactions (itching, rash) have been observed. In these cases, the dose is reduced or the drug is interrupted for a short time (1-2 days).

The above side effects occur in less than 10% of patients.

Overdose

Symptoms: decreased appetite, bronchospasm, lacrimation, increased sweating, constriction of pupils, nystagmus, increased GI peristalsis, spontaneous defecation and urination, vomiting, jaundice, bradycardia, intracardiac conduction disorders, arrhythmias, reduced BP, anxiety, restlessness, agitation, fear, ataxia, seizures, coma, speech disorders, drowsiness, general weakness.

Treatment: in case of tablet overdose – gastric lavage. Administration of m-cholinolytics, including atropine, cyclodol, methacin, etc.; symptomatic therapy.